

**UCB INC., ET AL.**

**v.**

**ACCORD HEALTHCARE INC., ET AL.**

**DeForest McDuff, Ph.D.**  
*Commercial Success*


**Direct Examination**

ARGENTUM Exhibit 117

Argentum Pharmaceuticals LLC v. Research Corporation Technologies, Inc.

IPR2016-0020

# License Offers



# Lack of Commercial Interest

## Pre-Eli Lilly License

JTX-134, The Squibb Inst. for Medical Research, May 1985

early stage of development and **lack of commercial interest**.

*JTX-134 (RCT\_VIM 0009731)*

PTX-252, Boehringer Ingelheim Ltd., May 1985

Based on the present profile of the agents, we feel they **would not offer a significant market** advantage over current treatments for neurological dis-

*PTX-252 (RCT\_VIM 0009728)*

PTX-255, Norwich Eaton Pharmaceuticals, Inc., Aug. 1985

We have **reviewed** your submission regarding a series of new amino acid anticonvulsant drugs, developed at the University of Houston, **with our marketing and development groups** and have reached the conclusion that we **must decline interest** in this opportunity.

*PTX-255 (RCT\_VIM 0009717)*

JTX-132, Organon Inc., October 1985

Organon Inc. has **no interest** in undertaking development

*JTX-132 (RCT\_VIM 0009684)*

JTX-130, Alza Corp., November 1985

matter and have determined that we have **no interest in obtaining a license** for this

## Post-Eli Lilly License

JTX-128, McNeil Pharmaceutical, Jun

advanced stage of development. Based on the data provided, **the profile of your compounds offers any advantage** over those we are currently working on.

*JTX-128 (RCT\_VIM 0009608)*

## Post-'551 Patent Filing

JTX-143, Merck, January 1998

Committee. We regret that there is **no current interest** in pursuing this opportunity. The Merck Research Laboratories (MRL) indicate that **compounds with profiles similar** to the profile of ADD 234037.


*JTX-143 (HAR\_VIM 0054314)*

JTX-119, Pfizer, August 1998


Unfortunately, Pfizer has elected **not to pursue** the anti-epileptic therapeutic area with this compound as a potential **business**

*JTX-119 (HAR\_VIM 0054334)*

# Development Disincentives



# Expected Patent Rights



**JTX-133, Correspondence between Norwich Eaton Pharmaceuticals, Inc. to Research Corp. re "Project No. 069-1397," 8/9/1985.**

If I do not hear from you by August 30, 1985, I will assume that your firm would have no interest in developing a compound covered by **patent rights** under an appropriate licensing arrangement.

*JTX-133 at 2 (RCT\_VIM 0009692)*

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.